S1 EP2: Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction

Episode 2 - Potential Treatment Options with a Focus on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction

We are joined by Prof Michael Böhm. He is the director of the Clinic for Internal Medicine III and Chief of Cardiology at the University of the Saarland University in Germany. He has a special interest in pathophysiology and treatment of heart failure and has been the principal investigator of several multi-centre clinical trials. He has written more than 700 original papers, book chapters and review articles and is the past president of the German Society of Cardiology.

In this episode, we will discuss the latest promising results of sodium-glucose cotransporter-2 (SGLT-2 inhibitor) empagliflozin in the EMPEROR-Preserved trials. In the previous podcast with Prof Anker, we heard that this class of drug is offering more options to patients and clinicians so we will explore this in more detail with Prof. Böhm.

Reference link:

https://www.nejm.org/doi/full/10.1056/NEJMoa2107038

“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”. 

“Not intended for US & UK based healthcare professionals”.